Mayne Pharma Launches Temozolomide Capsules in U.S. – Generic Alternative to Temodar®
Mayne Pharma Inc. (Mayne Pharma) is pleased to announce the U.S. launch of temozolomide capsules, 5mg, 20mg, 100mg, 140mg, 180mg and 250mg, which is a generic version of branded Temodar®. Temozolomide capsules are indicated for the treatment of adult patients with newly diagnosed cancerous... - November 23, 2016
Mayne Pharma Launches Budesonide Capsules in the United States
Mayne Pharma announces the U.S. launch of budesonide capsules in a 3 mg dose. Budesonide is a generic alternative to Entocort EC®, which is used as a treatment for patients with mild to moderate Crohn’s disease. The capsules reflect the company's focus on developing and manufacturing controlled-release and potent pharmaceuticals. - October 29, 2016
Mayne Pharma Closes $652 Million Acquisition of Generic Drug Portfolio from Teva and Allergan
The deal was part of the largest generic drug divestiture overseen by the Federal Trade Commission and Mayne Pharma acquired the greatest number of products. The newly acquired portfolio propels Mayne Pharma into the top 25 retail generic pharma companies in the United States, and the second largest provider of generic oral contraceptives. - August 05, 2016
Mayne Pharma's New $65M Facility Will Double U.S. Manufacturing Capacity, Expand Contract Services
At an event celebrating the start of construction, Mayne Pharma shared new details about its planned $65-million, 126,000-square-foot oral-dose facility in Greenville, N.C. The new facility will double the company's U.S. manufacturing capacity and introduce commercial-scale fluid-bed processing capacity for modified-release bead/pellet drugs. Space within the company's existing facility will be repurposed to expand contract analytical and formulation development services offered by Metrics. - September 26, 2015
Mayne Pharma to Invest $65m in Major Manufacturing Expansion in North Carolina
The company will invest $65 million to significantly expand facilities and equipment at its site in Greenville, N.C. Plans include greenfield construction of a new, 126,000-square-foot oral-dose commercial manufacturing facility, doubling U.S. manufacturing capacity, plus re-urposing of existing space to expand contract services. - August 29, 2015
Mayne Pharma Appoints Blake Cullen VP Business Development for U.S. Generics
He brings 15+ years of pharma industry experience in strategic planning, mergers and acquisitions, and product in-licensing and out-licensing. - June 16, 2014